• Based on 40 years of research into novel brain mechanisms that challenges accepted dogma.
  • Addresses the question of why only certain cells are primarily vulnerable in AD.
  • Pioneers a novel theory of the AD neurodegenerative process that for the first-time accounts for all the known clinical facts.
  • Identifies the key pivotal, toxic molecule (T14) underlying this pathological process. Demonstrates that this toxin is a feature of the AD brain where it is doubled in post-mortem midbrains and shows that neurodegeneration is an appropriate re-activation of development driven by the toxin, T14.
  • Is developing a possible blood test whereby this toxic molecule could act as a biomarker.
  • Identifies the molecular target (alpha7 nicotinic receptor) of the toxin where it enhances calcium entry, thereby inducing excitotoxicity and further proliferation of the receptor itself (Figure-green), thus perpetuating a feedforward cycle of neurodegeneration.
  • Designs a blocker of the toxin action at this receptor that could lead to an effective therapeutic drug Neuro-Bio has been granted a patent on a novel manner of inhibiting the binding of T14, by means of a cyclized peptide (Technology).The company is developing its pipeline of potential therapeutic drugs using the linear peptide variants as templates to design small molecules that will access the brain and for the first time stabilize cell loss by inhibiting the excitotoxic effect of T14 (Figure) and hence eventually treat this debilitating disease effectively.
Neuro-Bio Ltd
Building F5
Culham Science Centre
OX14 3DB
United Kingdom

+44 (0) 1235 420 085


© All Rights Reserved NeuroBio

ArabicChinese (Simplified)EnglishRussian